Lymphoma News and Features

Coping With Peripheral T-Cell Lymphoma

January 16, 2012

Peripheral T-cell lymphoma (PTCL) is a rare and aggressive form of cancer. This fact sheet explains the condition to newly diagnosed patients and provides sources of support.
 

Using ESAs in patients with cancer-related anemia

Sarah Wenger, PharmD; Lisa A. Thompson, PharmD, BCOP January 13, 2012

Although the risks of erythropoietin-stimulating agents can outweigh the benefits, select patients may benefit from these drugs.
 

Stem cell treatment does not improve overall survival in follicular lymphoma

Delicia Honen Yard January 12, 2012

High-dose chemotherapy combined with autologous stem cell transplantation did not improve overall survival in previously untreated adult patients with follicular lymphoma.
 

Cutaneous melanoma begets cutaneous melanoma

Delicia Honen Yard January 06, 2012

Continued skin surveillance is important for survivors of cutaneous melanoma (CM), indicate findings showing that this is the most common second primary cancer among persons with a first CM.
 

Intensive chemotherapy greatly improved survival for lymphoma patients

Delicia Honen Yard December 12, 2011

Survival improved significantly for persons younger than 60 years with diffuse large B-cell lymphoma when they underwent intensified chemotherapy compared with the standard regimen.
 

Older blood cancer patients may benefit from cell transplant regimen

Delicia Honen Yard November 22, 2011

A regimen using minimal-intensity radiation therapy before bone marrow or stem cell transplantation may work for older patients who cannot tolerate stronger pretransplant treatment.
 

Arthritis drugs may raise risk of skin cancer

Delicia Honen Yard September 30, 2011

Tumor necrosis factor (TNF) inhibitors—biologic agents used in the treatment of rheumatoid arthritis—appear to increase the risk of skin cancer, including melanoma.
 

New hope for half-match bone marrow transplant in blood cancer

Delicia Honen Yard September 16, 2011

A small study has demonstrated an improved process for making half-matched bone marrow or stem cell transplants for persons with blood cancer more successful.
 

Genetic variation sets stage for second cancer after childhood Hodgkin

Delicia Honen Yard August 17, 2011

Two small genetic variations can predict which patients with Hodgkin lymphoma are most likely to develop radiation-induced second cancers years after treatment, revealed a recent study.
 

New cancer patients benefit from full access to medical records

Delicia Honen Yard June 14, 2011

Allowing full access to personal medical records increases satisfaction but not anxiety in people who have recently been diagnosed with cancer, according to the findings of a recent study.
 

Lymphoma Clinical Trials

Clinical Trial: Temsirolimus, Bendamustine and Rituximab for Relapsed Follicular Lymphoma or Mantle Cell Lymphoma

Clinical Trial: Biaxin Based Antibiotic Therapy in Previously Untreated, Advanced Stage Indolent Lymphoma

Clinical Trial: Imexon for Relapsed Follicular and Aggressive Lymphomas

Clinical Trial: Study of Canfosfamide in Refractory or Relapsed Mantle Cell, Diffuse Large B Cell Lymphoma and Multiple Myeloma

Clinical Trial: Bortezomib, Ifosfamide, Carboplatin, and Etoposide, With or Without Rituximab, in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin Lymphoma

Free CE from mycme.com

Discussions on Emerging Concepts and Controversies in the Treatment of Patients with Advanced Non-Small Cell Lung Cancer

2.00 / AMA PRA Category 1 Credit(s)TM
This program reviews developments in maintenance therapy and evaluates the relevance of tumor histology and biomarker analysis for the management of NSCLC patients.
 

Cancer care is expensive.
CancerCare can help.


Connect Booklets
 Subscribe to the RSS for this page  [view all our RSS feeds here]

Web Exclusives

Psychosocial approach useful in managing cancer pain

February 03, 2012

Psychosocial interventions, including skills instruction and education, can help reduce pain in persons with cancer, confirm the results of a recent meta-analysis.
 

Experimental agent slows progression of colorectal cancer

February 02, 2012

The investigational drug regorafenib conferred a statistically significant survival benefit in patients with metastatic colorectal cancer in whom no standard therapy was effective.
 

In HER2 breast cancer, lapatinib works better with trastuzumab than without

February 01, 2012

Lapatinib is not as effective as trastuzumab against (HER2)-positive breast cancer, but combining the two nearly doubles the effectiveness seen with either one alone.
 

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization.

Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions